Mucosis B.V. develops prophylactic vaccines using a novel adjuvant platform that enables a more natural immune response as well as a broad base of protection.

Mucosis’s lead vaccine candidate, SynGEM™, is designed to prevent infections with Respiratory Syncytial Virus (RSV), which affect annualy over 60 million people worldwide. An RSV vaccine does not yet exist.

Portfolio: MedSciences Seed Fund B.V. and MedSciences Capital II B.V.

Current product development stage: clinical proof of concept for the technology, phase I clinical trial for RSV programme.